Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
about
Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.Current treatment options for psoriatic arthritis: spotlight on abatacept.Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives
P2860
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Efficacy and safety of abatace ...... study in psoriatic arthritis.
@en
type
label
Efficacy and safety of abatace ...... study in psoriatic arthritis.
@en
prefLabel
Efficacy and safety of abatace ...... study in psoriatic arthritis.
@en
P2093
P2860
P1476
Efficacy and safety of abatace ...... study in psoriatic arthritis.
@en
P2093
Alice B Gottlieb
Alyssa Johnsen
Marleen Nys
Oliver FitzGerald
Philip J Mease
Subhashis Banerjee
P2860
P304
P356
10.1136/ANNRHEUMDIS-2016-210724
P407
P577
2017-05-04T00:00:00Z